Drugs / LVIVO-TaVec200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07294625 | Dec 2025 → Mar 2027 expected | plasma cell myeloma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVIVO-TaVec200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07294625 ↗ |